
What happened
Texas Instruments Incorporated (NASDAQ: TXN) converted its recent manufacturing investment into a sharp cash-flow rebound in the third quarter.
Trailing twelve-month free cash flow reached $8.42 billion, up from $2.42 billion, while capital expenditures fell to $2.58 billion from $4.82 billion. The company defines free cash flow as cash from operations less capital expenditures.
Quarterly revenue rose 28% to $6.06 billion. Analog revenue grew 32%, embedded processing revenue grew 21%, and diluted earnings increased 77% to $2.62 per share.
Read more: Texas Instruments (TXN) stock analysis and investment case
Why it matters
The key change is that revenue growth and lower investment spending are reaching cash flow at the same time. Operating profit of $2.87 billion divided by revenue produces a 47.5% operating margin, up about 12.4 percentage points from a year earlier.
That strengthens the case that the expanded internal manufacturing network can support higher cash generation after a capital-intensive buildout. Trailing free cash flow improved by $6.01 billion, and free cash flow represented 40.6% of trailing revenue compared with 14.0% in the prior period.
The harder question is utilization. Semiconductor factories carry high fixed costs, so weaker demand can reduce returns even after capital spending falls. Texas Instruments Incorporated (NASDAQ: TXN) also continued returning cash to shareholders while funding a larger asset base.
Fourth-quarter guidance calls for revenue of $5.80 billion to $6.30 billion and earnings of $2.45 to $2.79 per share. That range leaves meaningful uncertainty about near-term demand.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Watch fourth-quarter revenue, gross margin and factory loadings. Cash conversion should remain strong if revenue holds near the upper half of guidance while capital spending stays below the prior buildout pace.
Also compare capital returns with free cash flow and debt. The current quarter shows better economics, but one period does not prove that all new capacity will earn attractive through-cycle returns.
The results improve the cash-flow case. They do not remove cyclical demand, pricing or utilization risk.
More from OptimistFi
- TXN stock: the Texas Instruments thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
Sources
- Texas Instruments Incorporated (NASDAQ: TXN) third-quarter 2026 Form 8-K — Filed October 21, 2026. Results filing and timing.
- Texas Instruments Incorporated (NASDAQ: TXN) third-quarter 2026 results — Revenue, profit, segment growth, cash flow, capital spending and fourth-quarter guidance.
- Texas Instruments Incorporated (NASDAQ: TXN) second-quarter 2026 Form 10-Q — Company identity, NASDAQ listing, manufacturing strategy and demand, utilization and capital-allocation risks.
- Photo: Texas Instruments Headquarters by Tony Webster — File photo taken April 16, 2019. It depicts the company headquarters sign and does not depict the October 2026 results.
- Photo license: CC BY 2.0 — Creator Tony Webster. Original resolution 7824 by 5219 pixels.
Read the full OptimistFi thesis on Texas Instruments Incorporated: https://optimistfi.com/stocks/TXN
See what would break the Texas Instruments Incorporated thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Texas Instruments Incorporated investment case, its status and the next test to watch live on the Texas Instruments Incorporated thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
